

Fidaxomicin for treatment of confirmed *Clostridioides difficile* infection (CDI) in adults

Areas where Protocol/Guideline applicable	Inpatients under the direction of Infectious Diseases specialist
Authorised Prescribers:	Restricted to prescribing by Infectious Diseases specialist
Indication for use	Treatment of <i>Clostridioides difficile</i>
Clinical condition Patient selection: Inclusion criteria	Treatment of confirmed <i>Clostridioides difficile</i> infection (CDI) in adults for first recurrence or refractory disease or for second and subsequent recurrences or ongoing refractory disease
Contra-indications	Known hypersensitivity
Precautions	Some patients with hypersensitivity reactions also reported a history of allergy to macrolides. Not for use in systemic infections as there is minimal systemic absorption
Proposed Place in Therapy	Treatment of laboratory confirmed CDI. Patient with severe or recurrent CDI.
Dosage	Fidaxomicin 200mg orally 12 hourly for 10 days
Duration of therapy	10 days
Important Drug Interactions	Fidaxomicin is not systemically absorbed. Other antibiotics should be ceased if no clear indication during treatment for CDI. Where ongoing antibiotic therapy is required, treatment for CDI should continue until the other antibiotics have ceased. Treatment with proton pump inhibitors, H2 antagonists and laxatives should be reviewed in patients with CDI and minimised where possible Cease fidaxomicin 24-48 hours prior to faecal microbiota transplantation (FMT)
Administration Instructions	Orally with or without food
Monitoring requirements	Frequency of diarrhoea will be the primary end point to monitor resolution of disease. Resolution of clinical signs and symptoms, improvement in laboratory parameters For patients with severe diseases, WCC, serum albumin, serum creatinine, any evidence of bowel perforation and signs of colonic wall thickening should be monitored.

Fidaxomicin for treatment of confirmed *Clostridioides difficile* infection (CDI) in adults



Management of Complications	n/a
Basis of Protocol/Guideline: (including sources of evidence, references)	<p>Mc Donald LC, Gerding DN, Johnson S et al Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clinical Infectious Diseases, Volume 66, Issue 7, 1 April 2018, Pages e1–e48</p> <p>Trubiano JA, Cheng AC, Korman TM et al; Australasian Society of Infectious Disease updated guideline for the management of Clostridium difficile infection in adults and children in Australia and New Zealand; Internal Medicine Journal, January 2016</p> <p>Sanford Guide 51st Ed. 2021. Dificid (fidaxomicin) Product information (MIMS)</p>
Groups consulted in development of this guideline	AMS pharmacist, ID Department, Antimicrobial Stewardship Committee for Prince of Wales Hospital and St George Hospital, AMS Clinical Application Advisory Group
AUTHORISATION	
Author (Name)	Adriana Chubaty ^{1,2} Suman Adhikari ^{1,2}
Position	1 - Senior Pharmacist - Antimicrobial Stewardship
Department	2 - Pharmacy Department, Prince of Wales Hospital 3- Pharmacy Department, St George Hospital
Department Contact	Adriana Chubaty Adriana.chubaty@health.nsw.gov.au Suman Adhikari suman.adhikari@health.nsw.gov.au
GOVERNANCE	
Enactment date <i>Reviewed</i> (Version 2) <i>Reviewed</i> (Version 3)	June 2021
Expiry date:	June 2024
Ratification date by SESLHD QUM Committee	3 rd June 2024
Chairperson, QUM Committee	Dr John Shephard
Version Number	1